Braidwell LP Trims Holdings in Harrow, Inc. $HROW

Braidwell LP cut its position in shares of Harrow, Inc. (NASDAQ:HROW) by 8.8% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 872,246 shares of the company’s stock after selling 84,593 shares during the quarter. Braidwell LP owned approximately 2.36% of Harrow worth $26,638,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the business. Quarry LP acquired a new stake in shares of Harrow during the first quarter worth $32,000. Raymond James Financial Inc. purchased a new position in shares of Harrow during the 2nd quarter worth about $48,000. State of Wyoming bought a new position in Harrow during the 1st quarter valued at $97,000. Strs Ohio bought a new position in Harrow during the 1st quarter valued at $149,000. Finally, SJS Investment Consulting Inc. grew its holdings in Harrow by 97.6% during the 2nd quarter. SJS Investment Consulting Inc. now owns 6,073 shares of the company’s stock worth $185,000 after acquiring an additional 3,000 shares in the last quarter. 72.76% of the stock is currently owned by institutional investors and hedge funds.

Harrow Stock Down 7.9%

HROW opened at $47.06 on Friday. The stock’s fifty day moving average is $40.24 and its 200-day moving average is $37.41. Harrow, Inc. has a one year low of $20.85 and a one year high of $51.30. The company has a market capitalization of $1.74 billion, a PE ratio of -470.55 and a beta of 0.07. The company has a debt-to-equity ratio of 5.21, a quick ratio of 2.52 and a current ratio of 2.72.

Harrow (NASDAQ:HROW) last released its earnings results on Monday, November 10th. The company reported $0.33 EPS for the quarter, topping analysts’ consensus estimates of $0.22 by $0.11. Harrow had a negative net margin of 1.99% and a positive return on equity of 28.71%. The business had revenue of $71.64 million for the quarter, compared to the consensus estimate of $73.70 million. On average, equities analysts predict that Harrow, Inc. will post -0.53 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on HROW shares. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $94.00 target price on shares of Harrow in a report on Tuesday, November 11th. HC Wainwright lifted their price target on shares of Harrow from $64.00 to $69.00 and gave the company a “buy” rating in a report on Wednesday, November 12th. B. Riley reaffirmed a “buy” rating and set a $74.00 price objective (up previously from $70.00) on shares of Harrow in a research report on Wednesday, October 1st. Zacks Research cut shares of Harrow from a “strong-buy” rating to a “hold” rating in a report on Friday, September 12th. Finally, BTIG Research restated a “buy” rating and set a $63.00 price objective on shares of Harrow in a research note on Wednesday, September 24th. Eight investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $71.43.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.